Who is eligible for clinical trial NCT04884360?

Participants must meet protocol criteria for Ovarian Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04884360 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-26

D9319C00001- 1L OC Mono Global RCT (NCT04884360)

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.

Who can join: Review the eligibility criteria below.

Location: Research Site — Santiago

Age range: 18 Years

🧪 Interventions in This Study

Olaparib (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (89 Sites)

Showing the first 25 of 89 sites.

Research Site — Santiago,
Research Site — Santiago,
Research Site — Temuco,
Research Site — Temuco,
Research Site — Viña del Mar,
Research Site — Baoji,
Research Site — Beijing,
Research Site — Beijing,
Research Site — Changchun,
Research Site — Changsha,
Research Site — Chengdu,
Research Site — Chengdu,
Research Site — Chongqing,
Research Site — Chongqing,
Research Site — Guangzhou,
Research Site — Guangzhou,
Research Site — Guiyang,
Research Site — Haikou,
Research Site — Hangzhou,
Research Site — Hefei,
Research Site — Hefei,
Research Site — Jiaxing,
Research Site — Jining,
Research Site — Lanzhou,
Research Site — Linyi,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts

Explore by condition: All Ovarian Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗